The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

September 8, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Maksim Kabakou/shutterstock.com

Maksim Kabakou/shutterstock.com

LONDON—Josef Smolen, MD, chair of rheumatology at the University of Vienna and former president of the European League Against Rheumatism (EULAR), expressed a “personal disappointment” in the development of useful biomarkers in the treatment of rheumatoid arthritis (RA).

You Might Also Like
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Biomarkers in Rheumatoid Arthritis Remain Elusive
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
Explore This Issue
September 2016
Also By This Author
  • Tips for Navigating Your First Medical Faculty Job

Even though a good portion of his life’s work has been researching biomarkers to help with targeting therapies, he lamented that the field has been full of promises that have mostly ended up dashed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“We have to do better, from my perspective,” said Dr. Smolen, speaking in a scientific debate at the 2016 EULAR Annual Congress. His debate counterpart—Ronald van Vollenhoven, MD, PhD, director of the Amsterdam Rheumatology and Immunology Center—was not particularly effusive about the progress of RA biomarkers, either, but painted a brighter picture.

Dr. Smolen said the hopes for biomarkers have been high.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We want to predict what’s going on,” he said. “We want to predict new treatment targets. … We want to predict bad outcome; we want to predict response to therapy. We want to know who will respond to which agents having four biological principals, plus jakinibs,” which all yield essentially similar results.

He pointed to the example of IL-17 inhibitors. Those who don’t respond to anti-tumor necrosis factor drugs tend to have increased levels of IL-17.

“What happens if we use IL-17 inhibitors, especially in patients who fail TNF inhibitors?” Dr. Smolen said. But the results, even in these patients, were disappointing.1

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“IL-17 looks like a biomarker of chronic inflammation, its levels are even elevated in patients who are inadequate responders to TNF inhibitors,” Dr. Smolen said. “But it fails as a target.”

Failed Potential Biomarkers

The list of potential biomarkers that have produced similarly dashed hopes is a long one, among them the IL-2 receptor, CD4 cells, IL-12 and IL-23.

“All of these have failed as therapeutic targets, even though we would have sworn that each one of them would bring a new era into rheumatoid arthritis treatment,” Dr. Smolen said.

The result is that, for the past 20 years, the field has relied on the same old markers: mainly swollen joint count, C-reactive protein, rheumatoid factor and anti-citrullinated protein antibody.

MBDA

One of the latest attempts to use biomarkers—the 12-component multiple biomarker disease activity score (MBDA), which is approved by the FDA for monitoring disease activity—has been called into question by some studies.

A 2016 study looked at data from the AMPLE trial of abatacept vs. adalimumab. The response graphs using DAS28-CRP are superimposable for the two drugs. But using the MBDA, adalimumab shows a greater effect, Dr. Smolen noted.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Biomarker, EULAR 2016, European League Against Rheumatism, progress, Research, Rheumatoid arthritis, rheumatologist, TreatmentIssue: September 2016

You Might Also Like:
  • Letters: Biomarkers for Rheumatoid Arthritis
  • Biomarkers in Rheumatoid Arthritis Remain Elusive
  • Janus Kinase Inhibitors Represent New Tool to Slow Rheumatoid Arthritis
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.